Novo Nordisk Says Alzheimer's Trial with Older GLP-1 Drug Fails

Novo Nordisk says Alzheimer's trial with older GLP-1 drug fails

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer’s patients, sending its share price down 10%

Novo Nordisk says Alzheimer's drug trial fails to meet main goal

Stocks making the biggest moves before the market: Novo Nordisk, Tesla, Alphabet, Oscar Health and more

Take a look at the companies making the biggest moves in premarket trading: Novo Nordisk - Shares fell 10% after the Danish pharmaceutical company's